Results 31 to 40 of about 4,771 (191)

Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis

open access: yesBiomolecules, 2019
Acetylation is an important post translational modification of histone that plays a role in regulation of physiological and pathological process in the body.
Hussein J. Hamam, Nades Palaniyar
doaj   +1 more source

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma [PDF]

open access: yesJournal of the Advanced Practitioner in Oncology, 2016
The PTCLs represent a rare and aggressive subgroup of NHLs that do not respond favorably to traditional chemotherapies. Since the majority of patients with PTCL experience disease relapse or disease that is refractory to previous agents, the continued development of novel targeted therapies is critical and necessary to improve outcomes in this ...
Katelyn, Hood, Arpita, Shah
openaire   +2 more sources

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

open access: yesFrontiers in Cell and Developmental Biology, 2020
Pralatrexate (Folotyn; PLX) and belinostat (Beleodaq; BLS) are registered for the treatment of patients with peripheral T-cell lymphoma (PTCL) and are being considered for other lymphomas.
Godefridus J. Peters   +6 more
doaj   +1 more source

The nature of the GRE influences the screening for GR-activity enhancing modulators. [PDF]

open access: yesPLoS ONE, 2017
Glucocorticoid resistance (GCR), i.e. unresponsiveness to the beneficial anti-inflammatory activities of the glucocorticoid receptor (GR), poses a serious problem in the treatment of inflammatory diseases.
Karen Dendoncker   +5 more
doaj   +1 more source

Belinostat metabolism pathway in human plasma with glucuronidation of belinostat as the dominant metabolism.

open access: yes, 2013
Belinostat metabolism pathway in human plasma with glucuronidation of belinostat as the dominant metabolism.
Win-Lwin Thuya (277890)   +16 more
core   +1 more source

A `one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer

open access: yesTranslational Oncology, 2021
Cancer cell phenotypes evolve during a tumor's treatment. In some cases, tumor cells acquire cancer stem cell-like (CSL) traits such as resistance to chemotherapy and diminished differentiation; therefore, targeting these cells may be therapeutically ...
Feng Chi   +10 more
doaj   +1 more source

Thiết kế, tổng hợp và đánh giá khả năng ức chế enzyme histone deacetylase (HDAC) in silico của một số dẫn xuất tương tự belinostat

open access: yesTạp chí Khoa học Đại học Cần Thơ, 2020
Belinostat là thuốc có khả năng ức chế enzyme HDAC khá tốt, được sử dụng điều trị các khối u ác tính về huyết học và khối u rắn. Trong nghiên cứu này, các dẫn xuất tương tự belinostat đã được tổng hợp thành công qua quy trình đơn giản và hiệu quả, phù ...
Nguyễn Cường Quốc   +12 more
doaj   +1 more source

Linfoma angioinmunoblástico de células T [PDF]

open access: yesGalicia Clínica, 2016
Se trata de un linfoma muy agresivo, con una mediana de supervivencia en torno a los 3 años. En cuanto al tratamiento, se han ensayado varias modalidades terapéuticas entre las cuales se encuentran los corticoides, los fármacos citotóxicos (vorinostat ...
Gargantilla P, Martin BM, Pintor E
doaj   +1 more source

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice [PDF]

open access: yes, 2013
Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F ...
Erichsen, Kamille Dumong   +17 more
core   +2 more sources

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy